|
|
Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time.
Sign up now!
Already registered? Please sign in.
Alternatively, please use our pay-per-view service. |
|
|

 |
Industry Events |
 |
Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022)
20-21 June 2022, Berlin, Germany
Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) is
held on June, 20-21, 2022 in Berlin, Germany. The Congress gathers
pharmaceutical companies, CMOs and CDMOs, governmental bodies together
with pharmaceutical equipment providers and service companies to discuss
the manufacturing and packaging processes of the pharmaceutical
industry. Among the participating companies are Bayer, Sandoz, Merck,
Novartis, Roche, Genveon, Samsung Biologics, Pfizer.
More info >> |
|
 |
News and Press Releases |
 |
Moderna Expands Its mRNA Pipeline with Three New Development Programs
CAMBRIDGE, MA / ACCESSWIRE / February 18, 2022 / Moderna, Inc.
(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA)
therapeutics and vaccines, today announced that it is expanding its mRNA
pipeline with three new development programs. This announcement
reflects the Company's commitment to expanding its portfolio building on
Moderna's experience with Spikevax®, its COVID-19 vaccine. The
development programs announced today are mRNA vaccine candidates against
herpes simplex virus (HSV), varicella-zoster virus (VSV) to reduce the
rate of shingles and a new checkpoint cancer vaccine. HSV and VZV are
latent viruses that remain in the body for life after infection and can
lead to life-long medical conditions. Moderna now has five vaccine
candidates against latent viruses in development, including against
cytomegalovirus (CMV), Epstein-Barr virus (EBV), Human immunodeficiency
virus (HIV), HSV and VZV.
More info >> |
|
|